1
|
Hamlin PA, Flinn IW, Wagner‐Johnston N, Burger JA, Coffey GP, Conley PB, Michelson G, Leeds JM, Der K, Kim Y, Sabalvaro‐Torres A, Birrell M, Pandey A, Curnutte JT, Patel MR. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. Am J Hematol 2019; 94:E90-E93. [PMID: 30592080 DOI: 10.1002/ajh.25387] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 12/21/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Paul A. Hamlin
- Division of Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York New York
- Department of Medicine Weill Cornell Medical College New York New York
| | - Ian W. Flinn
- Center for Blood Cancer Sarah Cannon Research Institute/Tennessee Oncology Nashville Tennessee
| | | | - Jan A. Burger
- Division of Cancer Medicine MD Anderson Cancer Center Houston Texas
| | - Greg P. Coffey
- Biology and Pharmacology Portola Pharmaceuticals, Inc. South San Francisco California
| | - Pamela B. Conley
- Biology and Pharmacology Portola Pharmaceuticals, Inc. South San Francisco California
| | - Glenn Michelson
- Clinical Development Portola Pharmaceuticals, Inc. South San Francisco California
| | - Janet M. Leeds
- Drug Metabolism and Pharmacokinetics Portola Pharmaceuticals, Inc. South San Francisco California
| | - Kenneth Der
- Pharmacokinetics Portola Pharmaceuticals, Inc. South San Francisco California
| | - Yvonne Kim
- Regulatory Affairs Portola Pharmaceuticals, Inc. South San Francisco California
| | | | - Matt Birrell
- Corporate Development Portola Pharmaceuticals, Inc. South San Francisco California
| | - Anjali Pandey
- Medicinal Chemistry and Chemical Development Portola Pharmaceuticals, Inc. South San Francisco California
| | - John T. Curnutte
- Research and Development Portola Pharmaceuticals, Inc. South San Francisco California
| | - Manish R. Patel
- Drug Development Unit Florida Cancer Specialists/Sarah Cannon Research Institute Sarasota Florida
| |
Collapse
|